Acacia Pharma Ltd., of Cambridge, UK, said its phase II study of APD403 to prevent chemotherapy-induced nausea and vomiting (CINV) demonstrated superior results compared to placebo at preventing delayed CINV (the period 24-120 hours following administration of chemotherapy), with the optimal dose improving complete response rate by 26 percent (p = 0.002) and significantly (p <0.05) reducing the incidence of both nausea and vomiting, compared to placebo.